Advertisement

Obesity Surgery

, Volume 27, Issue 9, pp 2471–2478 | Cite as

The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment

  • Hadya Elshakh
  • Khalid El-Ejji
  • Shahrad TaheriEmail author
Review Article

Abstract

Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.

Keywords

Botulinum toxin-A Endoscopy Obesity 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interested.

Statement of Informed Consent

None.

Statement of Human/Animal Rights

None.

References

  1. 1.
    Williams EP, Mesidor M, Winters K, et al. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4(3):363–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Stevens GA, Singh GM, Lu Y, et al National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metrics. 2012;10(1).Google Scholar
  3. 3.
    Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharm Econ. 2015;33(7):673–89.CrossRefGoogle Scholar
  4. 4.
    Dick JJ. Weight loss interventions for adult obesity: evidence for practice. Worldviews Evid-Based Nurs. 2004;1(4):209–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Yin J, Hou X. Complications of laparoscopic versus open bariatric surgical interventions in obesity management. Cell Biochem Biophys. 2014;70(2):721–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2016.Google Scholar
  7. 7.
    Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8(9):544–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Kendrick ML, Dakin GF. Surgical approaches to obesity. Mayo Clinic Proc. 2006;81(10).Google Scholar
  9. 9.
    Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;(2).Google Scholar
  10. 10.
    Swidnicka-Siergiejko A, Wróblewski E, Dabrowski A. Endoscopic treatment of obesity. Can J Gastroenterol. 2011;25(11):627–33.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon. 2013;67:87–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Jahn R, Scheller R. SNAREs—engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7(9):631–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Espinet-Coll E, Nebreda-Durán J, Gómez-Valero JA, et al. Current endoscopic techniques in the treatment of obesity. Rev Esp Enferm Dig. 2012;104(2):72–87.CrossRefPubMedGoogle Scholar
  15. 15.
    James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2003; 285(2).Google Scholar
  16. 16.
    Park M, Camilleri M. Gastric motor and sensory functions in obesity. Obes Res. 2005;13(3):491–500.CrossRefPubMedGoogle Scholar
  17. 17.
    Albanese A, Bentivoglio AR, Cassetta E, et al. Review article: the use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther. 1995;9(6):599–604.CrossRefPubMedGoogle Scholar
  18. 18.
    Gui D, De Gaetano A, Spada PL, et al. Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. Aliment Pharmacol Ther. 2000;14(6):829–34.CrossRefPubMedGoogle Scholar
  19. 19.
    Coskun H, Duran Y, Dilege E, et al. Effect on gastric emptying and weight reduction of botulinum toxin—a injection into the gastric antral layer: an experimental study in the obese rat model. Obes Surg. 2005;15(8):1137–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Rollnik JD, Meier PN, Manns MP, et al. Antral injections of botulinum a toxin for the treatment of obesity. Ann Intern Med. 2003;138(4):359–60.CrossRefPubMedGoogle Scholar
  21. 21.
    García-Compean D, Mendoza-Fuerte E, Martínez JA, et al. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol. 2005;29(8–9):789–91.CrossRefPubMedGoogle Scholar
  22. 22.
    Albani G, Petroni ML, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40(8):833–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Júnior AC, Savassi-Rocha PR, Coelho LG, et al. Botulinum a toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16(3):335–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese subjects: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17(6):732–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707–12.Google Scholar
  27. 27.
    Foschi D, Lazzaroni M, Sangaletti O, et al. Effects of intramural administration of botulinum toxin A on gastric emptying and eating capacity in obese subjects. Dig Liver Dis. 2008;40(8):667–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008;18(4):401–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Topazian M, Camilleri M, Enders FT, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013;11(2):145–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Xing J, Chen JD. Alterations of gastrointestinal motility in obesity. Obes Res. 2004;12(11):1723–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Bang C, Baik G, Shin I, et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest Endosc. 2015;81(5):1141–1149.e7.CrossRefPubMedGoogle Scholar
  32. 32.
    de Moura E, Bustamante F, Bernardo W. Reviewing the reviewers: critical appraisal of “effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression”. Gastrointest Endosc. 2016;83(2):478.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Clinical Research CoreWeill Cornell Medicine-Qatar, Qatar Foundation—Education CityDohaQatar
  2. 2.Department of GastroenterologyHamad Medical CorporationDohaQatar
  3. 3.National Obesity Centre, Qatar Metabolic InstituteHamad Medical CorporationDohaQatar
  4. 4.Department of MedicineWeill Cornell MedicineNew YorkUSA
  5. 5.Department of MedicineWeill Cornell MedicineDohaQatar

Personalised recommendations